4//SEC Filing
Gallagher Cam 4
Accession 0001725160-24-000030
CIK 0001725160other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 7:13 PM ET
Size
9.4 KB
Accession
0001725160-24-000030
Insider Transaction Report
Form 4
Gallagher Cam
Director
Transactions
- Sale
Common Stock
2024-02-02$11.54/sh−11,552$133,310→ 644,450 total - Award
Stock Option (Right to Buy)
2024-02-01+192,500→ 192,500 totalExercise: $11.69Exp: 2034-01-31→ Common Stock (192,500 underlying) - Award
Common Stock
2024-02-01+192,500→ 656,002 total
Footnotes (4)
- [F1]Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
- [F2]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001557832
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 7:13 PM ET
- Size
- 9.4 KB